Review



plasmids coding shrna control  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    OriGene plasmids coding shrna control
    Plasmids Coding Shrna Control, supplied by OriGene, used in various techniques. Bioz Stars score: 95/100, based on 151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pmc09502689-138-5-11?v=OriGene
    Average 95 stars, based on 151 article reviews
    plasmids coding shrna control - by Bioz Stars, 2026-08
    95/100 stars

    Images



    Similar Products

    95
    OriGene plasmids coding shrna control
    Plasmids Coding Shrna Control, supplied by OriGene, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pmc09502689-138-5-11?v=OriGene
    Average 95 stars, based on 1 article reviews
    plasmids coding shrna control - by Bioz Stars, 2026-08
    95/100 stars
      Buy from Supplier

    90
    Millipore the plasmids for producing lentivirus that code shrnas targeting mef2c and gfp (control)
    LAMZ induces Mef2c to enhance myogenesis and osteoblastogenesis. a mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with calcium signal inhibitors together with LAMZ. b mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells infected with <t>lentiviruses</t> encoding sh Mef2c . c Representative immunocytofluorescence images of the C2C12 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. Myosin heavy chain (red); nuclei (blue). Scale bar, 100 μm. d mRNA expression of Myog and Ppargc1a . e Representative ALP staining images of the MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. f Representative images of Alizarin Red S staining of MC3T3-E1 cells. g mRNA expression of osteoblastic genes and Ppargc1a . h mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with the PGC-1α inhibitor SR18292. Experiments were repeated 3 times with replicates of two wells. For the comparison of two groups, statistical analyses were carried out using Welch’s t test. For multiple comparisons, two–way ANOVA and Tukey’s multiple-comparison test were applied. The error bars show the mean ± s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; N.S. not significant
    The Plasmids For Producing Lentivirus That Code Shrnas Targeting Mef2c And Gfp (Control), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pmc09345981-318-4-16?v=Millipore
    Average 90 stars, based on 1 article reviews
    the plasmids for producing lentivirus that code shrnas targeting mef2c and gfp (control) - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Ribobio co plasmids coding for shrna targeting human foxo1 and scrambled shrna as negative control
    LAMZ induces Mef2c to enhance myogenesis and osteoblastogenesis. a mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with calcium signal inhibitors together with LAMZ. b mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells infected with <t>lentiviruses</t> encoding sh Mef2c . c Representative immunocytofluorescence images of the C2C12 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. Myosin heavy chain (red); nuclei (blue). Scale bar, 100 μm. d mRNA expression of Myog and Ppargc1a . e Representative ALP staining images of the MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. f Representative images of Alizarin Red S staining of MC3T3-E1 cells. g mRNA expression of osteoblastic genes and Ppargc1a . h mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with the PGC-1α inhibitor SR18292. Experiments were repeated 3 times with replicates of two wells. For the comparison of two groups, statistical analyses were carried out using Welch’s t test. For multiple comparisons, two–way ANOVA and Tukey’s multiple-comparison test were applied. The error bars show the mean ± s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; N.S. not significant
    Plasmids Coding For Shrna Targeting Human Foxo1 And Scrambled Shrna As Negative Control, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pmc06096113-151-9-17?v=Ribobio+co
    Average 90 stars, based on 1 article reviews
    plasmids coding for shrna targeting human foxo1 and scrambled shrna as negative control - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    93
    Addgene inc non coding control shrna
    Figure 3 | CYREN interaction with Ku in S and G2 inhibits cNHEJ. a, CYREN isoforms. b, Mean percentage of fused ends per metaphase. siNT, control non-targeting <t>siRNA;</t> siCY, CYREN-targeting siRNA. Error bars, s.e.m. ***P < 0.001, *P < 0.05; NS, not significant. One-way ANOVA, Sidak’s multiple comparison test. n, number of metaphases analysed. Experiment shown is representative of two biological replicates. c, Co-immunoprecipitation of CYREN-1–3×Flag with Ku70/80 in HEK293T cells. For gel source data, see Supplementary Fig. 1. d, Percentage of fusions ± upper and lower value of 95% confidence intervals, Wilson–Brown test. ***P < 0.001, **P < 0.01;
    Non Coding Control Shrna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pm28959974-304-1-12?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    non coding control shrna - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    90
    OriGene gfp gene-containing plasmids coding for shrna against hipk2 and scrambled control
    Figure 3 | CYREN interaction with Ku in S and G2 inhibits cNHEJ. a, CYREN isoforms. b, Mean percentage of fused ends per metaphase. siNT, control non-targeting <t>siRNA;</t> siCY, CYREN-targeting siRNA. Error bars, s.e.m. ***P < 0.001, *P < 0.05; NS, not significant. One-way ANOVA, Sidak’s multiple comparison test. n, number of metaphases analysed. Experiment shown is representative of two biological replicates. c, Co-immunoprecipitation of CYREN-1–3×Flag with Ku70/80 in HEK293T cells. For gel source data, see Supplementary Fig. 1. d, Percentage of fusions ± upper and lower value of 95% confidence intervals, Wilson–Brown test. ***P < 0.001, **P < 0.01;
    Gfp Gene Containing Plasmids Coding For Shrna Against Hipk2 And Scrambled Control, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmids+coding+shrna+control/pmc03700609-77-2-14?v=OriGene
    Average 90 stars, based on 1 article reviews
    gfp gene-containing plasmids coding for shrna against hipk2 and scrambled control - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    LAMZ induces Mef2c to enhance myogenesis and osteoblastogenesis. a mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with calcium signal inhibitors together with LAMZ. b mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c . c Representative immunocytofluorescence images of the C2C12 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. Myosin heavy chain (red); nuclei (blue). Scale bar, 100 μm. d mRNA expression of Myog and Ppargc1a . e Representative ALP staining images of the MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. f Representative images of Alizarin Red S staining of MC3T3-E1 cells. g mRNA expression of osteoblastic genes and Ppargc1a . h mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with the PGC-1α inhibitor SR18292. Experiments were repeated 3 times with replicates of two wells. For the comparison of two groups, statistical analyses were carried out using Welch’s t test. For multiple comparisons, two–way ANOVA and Tukey’s multiple-comparison test were applied. The error bars show the mean ± s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; N.S. not significant

    Journal: Bone Research

    Article Title: Simultaneous augmentation of muscle and bone by locomomimetism through calcium-PGC-1α signaling

    doi: 10.1038/s41413-022-00225-w

    Figure Lengend Snippet: LAMZ induces Mef2c to enhance myogenesis and osteoblastogenesis. a mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with calcium signal inhibitors together with LAMZ. b mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c . c Representative immunocytofluorescence images of the C2C12 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. Myosin heavy chain (red); nuclei (blue). Scale bar, 100 μm. d mRNA expression of Myog and Ppargc1a . e Representative ALP staining images of the MC3T3-E1 cells infected with lentiviruses encoding sh Mef2c and treated with LAMZ. f Representative images of Alizarin Red S staining of MC3T3-E1 cells. g mRNA expression of osteoblastic genes and Ppargc1a . h mRNA expression of Mef2c in the C2C12 cells and MC3T3-E1 cells treated with the PGC-1α inhibitor SR18292. Experiments were repeated 3 times with replicates of two wells. For the comparison of two groups, statistical analyses were carried out using Welch’s t test. For multiple comparisons, two–way ANOVA and Tukey’s multiple-comparison test were applied. The error bars show the mean ± s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.000 1; N.S. not significant

    Article Snippet: The plasmids for producing lentivirus that code shRNAs targeting Mef2c and gfp (control) were purchased from Sigma-Aldrich.

    Techniques: Expressing, Infection, Staining

    Figure 3 | CYREN interaction with Ku in S and G2 inhibits cNHEJ. a, CYREN isoforms. b, Mean percentage of fused ends per metaphase. siNT, control non-targeting siRNA; siCY, CYREN-targeting siRNA. Error bars, s.e.m. ***P < 0.001, *P < 0.05; NS, not significant. One-way ANOVA, Sidak’s multiple comparison test. n, number of metaphases analysed. Experiment shown is representative of two biological replicates. c, Co-immunoprecipitation of CYREN-1–3×Flag with Ku70/80 in HEK293T cells. For gel source data, see Supplementary Fig. 1. d, Percentage of fusions ± upper and lower value of 95% confidence intervals, Wilson–Brown test. ***P < 0.001, **P < 0.01;

    Journal: Nature

    Article Title: Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.

    doi: 10.1038/nature24023

    Figure Lengend Snippet: Figure 3 | CYREN interaction with Ku in S and G2 inhibits cNHEJ. a, CYREN isoforms. b, Mean percentage of fused ends per metaphase. siNT, control non-targeting siRNA; siCY, CYREN-targeting siRNA. Error bars, s.e.m. ***P < 0.001, *P < 0.05; NS, not significant. One-way ANOVA, Sidak’s multiple comparison test. n, number of metaphases analysed. Experiment shown is representative of two biological replicates. c, Co-immunoprecipitation of CYREN-1–3×Flag with Ku70/80 in HEK293T cells. For gel source data, see Supplementary Fig. 1. d, Percentage of fusions ± upper and lower value of 95% confidence intervals, Wilson–Brown test. ***P < 0.001, **P < 0.01;

    Article Snippet: The non-coding control shRNA in pLKO.1 was obtained from D. Sabatini via Addgene (Plasmid 186432).

    Techniques: Control, Comparison, Immunoprecipitation